Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Prolymphocytic 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms 2Uveal Melanoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocythemia, Essential 1

Interventions

Pharmacogenomic Testing 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Chondrosarcoma, Clear Cell × Pharmacogenomic Testing × Clear all
NCT01267955 2026-04-13

Vismodegib in Treating Patients With Advanced Chondrosarcomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
45 enrolled 10 charts
Sarcoma

Chondrosarcoma, Clear Cell, Chondrosarcoma, Chondrosarcoma, Mesenchymal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡